» Articles » PMID: 29997515

Metabolomic Approach to Redox and Nitrosative Reactions in Cardiovascular Diseases

Overview
Journal Front Physiol
Date 2018 Jul 13
PMID 29997515
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Metabolomics, also referred to as metabonomics, is one of the most recent innovative technologies in medicine. It offers a direct functional read-out of phenotypes by the detection, identification, and quantification of a large number of metabolites within a biological sample such as urine and blood. Metabolites (<1500 Da) represent the output of cellular metabolism, accounting for expression and activity of genes, transcripts, and proteins, and offering unique insights into small molecule regulation, which may uncover new biochemical patterns. Metabolomics research has considerable potential for translating the metabolic fingerprint into personalized therapeutic strategies. Within the field of interest, cardiovascular disease (CVD) is one of the most developed areas. However, CVD remains the leading cause of death worldwide with a marked increase in mortality rates over the past six decades. In this scenario, recent findings indicate the important role of redox and nitrosative (RN) reactions in CVD development and progression. RN reactions are generally involved in the homeostatic modulation of a wide number of cellular and organ functions. Conversely, the imbalance of these reactions may lead to a condition of allostasis that in turn can cause CVD. The aim of this review is to highlight how the use of metabolomics may be useful for the study of RN reactions related to CVD, providing a tool to understand the mechanisms underlying reactions that could lead to impaired ROS or RNS formation.

Citing Articles

Untargeted Metabolic Profiling of Extracellular Vesicles of SARS-CoV-2-Infected Patients Shows Presence of Potent Anti-Inflammatory Metabolites.

Alzahrani F, Razeeth Shait Mohammed M, Alkarim S, Azhar E, El-Magd M, Hawsawi Y Int J Mol Sci. 2021; 22(19).

PMID: 34638812 PMC: 8509011. DOI: 10.3390/ijms221910467.


Redox Metabolism Measurement in Mammalian Cells and Tissues by LC-MS.

Petrova B, Warren A, Vital N, Culhane A, Maynard A, Wong A Metabolites. 2021; 11(5).

PMID: 34068241 PMC: 8153172. DOI: 10.3390/metabo11050313.


Metabolomic Analysis of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors.

Caocci G, Deidda M, Noto A, Greco M, Simula M, Mulas O J Clin Med. 2020; 9(4).

PMID: 32326001 PMC: 7231160. DOI: 10.3390/jcm9041180.


New avenues in cardio-oncology.

Sala V, Li M, Ghigo A Aging (Albany NY). 2019; 11(4):1075-1076.

PMID: 30728321 PMC: 6402516. DOI: 10.18632/aging.101817.

References
1.
Czerny M, Baumer H, Kilo J, Lassnigg A, Hamwi A, Vukovich T . Inflammatory response and myocardial injury following coronary artery bypass grafting with or without cardiopulmonary bypass. Eur J Cardiothorac Surg. 2000; 17(6):737-42. DOI: 10.1016/s1010-7940(00)00420-6. View

2.
Kordalewska M, J Markuszewski M . Metabolomics in cardiovascular diseases. J Pharm Biomed Anal. 2015; 113:121-36. DOI: 10.1016/j.jpba.2015.04.021. View

3.
Griffin J, Atherton H, Shockcor J, Atzori L . Metabolomics as a tool for cardiac research. Nat Rev Cardiol. 2011; 8(11):630-43. DOI: 10.1038/nrcardio.2011.138. View

4.
Usui M, Matsuoka H, Miyazaki H, Ueda S, Okuda S, Imaizumi T . Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure. Life Sci. 1998; 62(26):2425-30. DOI: 10.1016/s0024-3205(98)00225-2. View

5.
Mullens W, Abrahams Z, Francis G, Skouri H, Starling R, Young J . Sodium nitroprusside for advanced low-output heart failure. J Am Coll Cardiol. 2008; 52(3):200-7. DOI: 10.1016/j.jacc.2008.02.083. View